José de Jesús Vidal-Mayo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
José de Jesús Vidal-Mayo has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Ashuin Kammar-García
Dirección de Investigación, Instituto Nacional de Geriatría, Mexico City, Mexico
3 shared publications - Javier Mancilla-Galindo
Institute for Risk Assessment Sciences, Utrecht University
3 shared publications - Addí Rhode Navarro-Cruz
Departamento de Bioquímica-Alimentos, Facultad de Ciencias Químicas, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
2 shared publications G. Reyes-Velázquez
Instituto Mexicano del Seguro Social
2 shared publications- Juan Mauricio Vera-Zertuche
Endocrinology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México
2 shared publications - Orietta Segura-Badilla
Universidad del Bío-Bío, Facultad de Ciencias de la Salud y de los Alimentos, Santiago, Chile
2 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0347761
Outcomes in acute pulmonary embolism and their association with adherence to international recommendations around COVID-19 pandemic-induced hospital-strain: The experience in a Mexican tertiary care center
Background: Lack of adherence to international recommendations leads to worse outcomes. During the COVID-19 pandemic, the total number and proportion of hospitalized patients increased, consequently straining hospital care and hindering adherence. Aims: To evaluate adherence to clinical guidelines at our center, before, during, and shortly after the COVID-19 pandemic-induced hospital strain, and its association with clinical outcomes, using a random, balanced retrospective cohort. Design: A balanced and randomized sample of 50 patients per year between 2019 and 2022 was drawn from electronic medical records and analyzed with multivariable and logistic regression models. The primary outcome was a composite of in-hospital death, hemodynamic decompensation within the first 7 days, and in-hospital bleeding. Results: The global non-adherence in our study was 45.4%. The main risk factors for non-adherence were any mortality risk classification above low-risk PE and a PESI class different from class I, with ORs of 3.47 (95% CI 2.07–5.82) and 1.57 (95% CI 1.04–2.37), respectively. In both periods (COVID-19 season and non-COVID-19 season), non-adherent management strongly correlated with the composite outcome, OR = 2.36 (95% CI, 1.23–4.54). Non-adherence was also associated with worse in-hospital outcomes, with an incidence rate of the composite outcome of 21.08 per 1000 days/person (95% CI 10.97–40.51) and 47.7 per 1000 days/person (95% CI 33.39–67.50), and an attributable risk of 1.09% (95% CI −8.47%−10.64%). Conclusions: Overall, our findings highlight the need to prioritize human and material resources to ensure adherence to the standards of care for PE patients.
- 29 April 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (4) , e0347761
Open AccessOutcomes in acute pulmonary embolism and their association with adherence to international recommendations around COVID-19 pandemic-induced hospital-strain: The experience in a Mexican tertiary care center
Background: Lack of adherence to international recommendations leads to worse outcomes. During the COVID-19 pandemic, the total number and proportion of hospitalized patients increased, consequently straining hospital care and hindering adherence. Aims: To evaluate adherence to clinical guidelines at our center, before, during, and shortly after the COVID-19 pandemic-induced hospital strain, and its association with clinical outcomes, using a random, balanced retrospective cohort. Design: A balanced and randomized sample of 50 patients per year between 2019 and 2022 was drawn from electronic medical records and analyzed with multivariable and logistic regression models. The primary outcome was a composite of in-hospital death, hemodynamic decompensation within the first 7 days, and in-hospital bleeding. Results: The global non-adherence in our study was 45.4%. The main risk factors for non-adherence were any mortality risk classification above low-risk PE and a PESI class different from class I, with ORs of 3.47 (95% CI 2.07–5.82) and 1.57 (95% CI 1.04–2.37), respectively. In both periods (COVID-19 season and non-COVID-19 season), non-adherent management strongly correlated with the composite outcome, OR = 2.36 (95% CI, 1.23–4.54). Non-adherence was also associated with worse in-hospital outcomes, with an incidence rate of the composite outcome of 21.08 per 1000 days/person (95% CI 10.97–40.51) and 47.7 per 1000 days/person (95% CI 33.39–67.50), and an attributable risk of 1.09% (95% CI −8.47%−10.64%). Conclusions: Overall, our findings highlight the need to prioritize human and material resources to ensure adherence to the standards of care for PE patients.
- Open Access
- 20 September 2022
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
- Vol. 27 (4)
Evaluación de la escala Status Epilepticus Severity Score (STESS) como predictor de la mortalidad intrahospitalaria en pacientes con estado: Estudio observacional retrospectivo
Antecedentes. El estado epiléptico (EE) es una emergencia médica caracterizada por actividad epiléptica continua o recurrente con una alta mortalidad. La escala STESS (Status Epilepticus Severity Score) permite evaluar el pronóstico de pacientes con EE. Objetivo. Describir las características clínicas de los pacientes con EE en nuestro centro, determinar las variables asociadas a mortalidad y determinar la capacidad predictora de la escala STESS para mortalidad intrahospitalaria. Material y métodos. Estudio de cohorte retrospectivo. Se incluyeron pacientes con diagnóstico de EE durante el periodo de 2000-2020. Se aplicó la escala pronóstica STESS a todos los pacientes. Se obtuvieron datos de las características clínicas y mortalidad intrahospitalaria. Se aplicó un análisis de regresión de Cox para determinar el riesgo de mortalidad por cada punto de la escala STESS, y se calculó el área bajo la curva ROC para determinar la capacidad de discriminación de la escala. Resultados. Fueron incluidos 60 pacientes. La presentación clínica predominante fue el EE convulsivo generalizado en 51.7%, las etiologías más frecuentes fueron sintomáticas agudas (46.7%). La mortalidad hospitalaria fue 40%. El riesgo de mortalidad se incrementa un 38% por cada punto de STESS (B=0.38, HR=1.48, IC95%:1.13-1.94, p=0.005). El área bajo la curva ROC de la escala STESS fue 0.72 con un punto de corte óptimo ≥3 puntos para discriminación de mortalidad hospitalaria. Conclusiones. La escala STESS se asocia significativamente con la mortalidad intrahospitalaria y puede ser usada como predictor de los desenlaces adversos en pacientes con EE.
- 20 September 2022
- Published by Instituto Mexicano del Seguro Social in Archivos de Neurociencias
- Vol. 27 (4)
Open AccessEvaluación de la escala Status Epilepticus Severity Score (STESS) como predictor de la mortalidad intrahospitalaria en pacientes con estado: Estudio observacional retrospectivo
Antecedentes. El estado epiléptico (EE) es una emergencia médica caracterizada por actividad epiléptica continua o recurrente con una alta mortalidad. La escala STESS (Status Epilepticus Severity Score) permite evaluar el pronóstico de pacientes con EE. Objetivo. Describir las características clínicas de los pacientes con EE en nuestro centro, determinar las variables asociadas a mortalidad y determinar la capacidad predictora de la escala STESS para mortalidad intrahospitalaria. Material y métodos. Estudio de cohorte retrospectivo. Se incluyeron pacientes con diagnóstico de EE durante el periodo de 2000-2020. Se aplicó la escala pronóstica STESS a todos los pacientes. Se obtuvieron datos de las características clínicas y mortalidad intrahospitalaria. Se aplicó un análisis de regresión de Cox para determinar el riesgo de mortalidad por cada punto de la escala STESS, y se calculó el área bajo la curva ROC para determinar la capacidad de discriminación de la escala. Resultados. Fueron incluidos 60 pacientes. La presentación clínica predominante fue el EE convulsivo generalizado en 51.7%, las etiologías más frecuentes fueron sintomáticas agudas (46.7%). La mortalidad hospitalaria fue 40%. El riesgo de mortalidad se incrementa un 38% por cada punto de STESS (B=0.38, HR=1.48, IC95%:1.13-1.94, p=0.005). El área bajo la curva ROC de la escala STESS fue 0.72 con un punto de corte óptimo ≥3 puntos para discriminación de mortalidad hospitalaria. Conclusiones. La escala STESS se asocia significativamente con la mortalidad intrahospitalaria y puede ser usada como predictor de los desenlaces adversos en pacientes con EE.
- Open Access
- 1 January 2022
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 63 (1) , 3-13
Delirium and Associated Factors in a Cohort of Hospitalized Patients With Coronavirus Disease 2019
- 1 January 2022
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 63 (1) , 3-13
Open AccessDelirium and Associated Factors in a Cohort of Hospitalized Patients With Coronavirus Disease 2019
- Open Access
- 26 November 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, 1-37
Development and validation of the patient history COVID-19 (PH-Covid19) scoring system: a multivariable prediction model of death in Mexican patients with COVID-19
Most of the existing prediction models for COVID-19 lack validation, are inadequately reported or are at high risk of bias, a reason which has led to discourage their use. Few existing models have the potential to be extensively used by healthcare providers in low-resource settings since many require laboratory and imaging predictors. Therefore, we sought to develop and validate a multivariable prediction model of death in Mexican patients with COVID-19, by using demographic and patient history predictors. We conducted a national retrospective cohort study in two different sets of patients from the Mexican COVID-19 Epidemiologic Surveillance Study. Patients with a positive reverse transcription-polymerase chain reaction for SARS-CoV-2 and complete unduplicated data were eligible. In total, 83 779 patients were included to develop the scoring system through a multivariable Cox regression model; 100 000, to validate the model. Eight predictors (age, sex, diabetes, chronic obstructive pulmonary disease, immunosuppression, hypertension, obesity and chronic kidney disease) were included in the scoring system called PH-Covid19 (range of values: −2 to 25 points). The predictive model has a discrimination of death of 0.8 (95% confidence interval (CI) 0.796–0.804). The PH-Covid19 scoring system was developed and validated in Mexican patients to aid clinicians to stratify patients with COVID-19 at risk of fatal outcomes, allowing for better and efficient use of resources.
- 26 November 2020
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 148, 1-37
Open AccessDevelopment and validation of the patient history COVID-19 (PH-Covid19) scoring system: a multivariable prediction model of death in Mexican patients with COVID-19
Most of the existing prediction models for COVID-19 lack validation, are inadequately reported or are at high risk of bias, a reason which has led to discourage their use. Few existing models have the potential to be extensively used by healthcare providers in low-resource settings since many require laboratory and imaging predictors. Therefore, we sought to develop and validate a multivariable prediction model of death in Mexican patients with COVID-19, by using demographic and patient history predictors. We conducted a national retrospective cohort study in two different sets of patients from the Mexican COVID-19 Epidemiologic Surveillance Study. Patients with a positive reverse transcription-polymerase chain reaction for SARS-CoV-2 and complete unduplicated data were eligible. In total, 83 779 patients were included to develop the scoring system through a multivariable Cox regression model; 100 000, to validate the model. Eight predictors (age, sex, diabetes, chronic obstructive pulmonary disease, immunosuppression, hypertension, obesity and chronic kidney disease) were included in the scoring system called PH-Covid19 (range of values: −2 to 25 points). The predictive model has a discrimination of death of 0.8 (95% confidence interval (CI) 0.796–0.804). The PH-Covid19 scoring system was developed and validated in Mexican patients to aid clinicians to stratify patients with COVID-19 at risk of fatal outcomes, allowing for better and efficient use of resources.
- Open Access
Development and Validation of the Patient History COVID-19 (PH-Covid19) Scoring System: A Multivariable Prediction Model of Death in Mexican Patients with COVID-19
Summary: We sought to develop and validate a multivariable prediction model of death in Mexican patients with COVID-19, by using demographic and patient history predictors. We conducted a national retrospective cohort in two different sets of patients from the Mexican COVID-19 Epidemiologic Surveillance Study. To develop the model, we included 264,026 patients tested for SARS-CoV-2 between February 28 and May 30, 2020. To validate the model, 592,160 patients studied between June 1 and July 23, 2020 were included. Patients with a positive RT-PCR for SARS-CoV-2 and complete unduplicated data were eligible. Demographic and patient history variables were analyzed through Multivariable Cox regression models to evaluate predictors to be included in the prognostic scoring system called PH-Covid19. 83,779 patients were included to develop the model; 100,000, to validate the model. Eight predictors (age, sex, diabetes, COPD, immunosuppression, hypertension, obesity, and CKD) were included in the PH-Covid19 scoring system (range of values: −2 to 25 points). The predictive model has a discrimination of death of 0.8 (95%CI:0.796-0.804). The PH-Covid19 scoring system was developed and validated in Mexican patients to aid clinicians to stratify patients with COVID-19 at risk of fatal outcomes, allowing for better and efficient use of resources.
Open AccessDevelopment and Validation of the Patient History COVID-19 (PH-Covid19) Scoring System: A Multivariable Prediction Model of Death in Mexican Patients with COVID-19
Summary: We sought to develop and validate a multivariable prediction model of death in Mexican patients with COVID-19, by using demographic and patient history predictors. We conducted a national retrospective cohort in two different sets of patients from the Mexican COVID-19 Epidemiologic Surveillance Study. To develop the model, we included 264,026 patients tested for SARS-CoV-2 between February 28 and May 30, 2020. To validate the model, 592,160 patients studied between June 1 and July 23, 2020 were included. Patients with a positive RT-PCR for SARS-CoV-2 and complete unduplicated data were eligible. Demographic and patient history variables were analyzed through Multivariable Cox regression models to evaluate predictors to be included in the prognostic scoring system called PH-Covid19. 83,779 patients were included to develop the model; 100,000, to validate the model. Eight predictors (age, sex, diabetes, COPD, immunosuppression, hypertension, obesity, and CKD) were included in the PH-Covid19 scoring system (range of values: −2 to 25 points). The predictive model has a discrimination of death of 0.8 (95%CI:0.796-0.804). The PH-Covid19 scoring system was developed and validated in Mexican patients to aid clinicians to stratify patients with COVID-19 at risk of fatal outcomes, allowing for better and efficient use of resources.